Zejula

Active Ingredient(s): Niraparib
FDA Approved: * March 27, 2017
Pharm Company: * TESARO INC
Category: Cancer

* This drug may consist of multiple approval dates, manufacturers, or distributors. If applicable, they would be listed below under "NDC Database Records".



Zejula Overview

Niraparib (trade name Zejula) is an orally active[1] small molecule PARP inhibitor developed by Tesaro to treat ovarian cancer. Niraparib was granted fast track designation by the US Food and Drug Administration (FDA), and Tesaro submitted a new drug application in 2016.[2] It was approved on 27 March 2017 in the US,[3] but is not approved in Europe as of June 2017[update]. Contents 1 Medical uses 2 Contraindications 3 Side effects 4 Interactions 5 Pharmacology 5.1 Mechanism of action...

Read more Zejula Details
Details May Include Instructions, Side Effects, Interactions, Etc. Drug monograph is from Wikipedia. All text is available under the terms of the GFDL (GNU Free Documentation License). Source: en.wikipedia.org/wiki/Niraparib

Recent Zejula Forums:

Be the first to start a discussion about this drug.

Possible Dosages for this and Related Drugs:

Niraparib
  • Capsule: 100mg
Note: Above list includes dosages for all drugs with the same combination of active ingredients.

NDC Database Records for Zejula: (1 result)

Sorted by National Drug Code
  • 69656-103 Zejula 100 mg Oral Capsule by Tesaro, Inc.

Other drugs which contain Niraparib or a similar ingredient: (1 result)





Note: All times displayed are GMT - 7.

This information has been independently compiled and is for informational purposes only. It is not intended to be a substitute for medical advice from a qualified healthcare professional; nor is it intended to diagnose, treat, cure or prevent any disease. For more details please see the Medical Disclaimer. Site content is Copyright © 2005-2017 MedsChat.com and is protected under U.S. and International Copyright laws. All Rights Reserved. This page was last updated on 24 August 2017.

We are committed to your privacy.

Copyright © 2005-2017 All Rights Reserved. MedsChat® and The People's Medicine Community® are registered trademarks of Limelight Innovations L.L.C.